Serum Zinc and Serum Magnesium in Chronic Liver Disease Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-01

Study Completion Date

2025-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational cross-sectional study is to assess the relationship between serum levels of magnesium and zinc in pediatric and adult patients with chronic liver disease and the clinic-laboratory variables.

Researchers will compare serum levels of zinc and magnesium in patients with chronic liver disease and healthy controls. Assess the correlation between serum zinc and magnesium and the presence and severity of chronic liver disease and cirrhosis.

Participants will be subjected to history taking, clinical examination, laboratory investigations, and abdominal ultrasonography.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hepatic Manifestations and Effect of Long COVID-19 on Patients With Chronic Liver Disease

NCT04998214

COVID-19

UNKNOWN

Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

NCT05249374

Hepatic Ascites

COMPLETED PHASE1

High Protein Diet Versus Normal Protein Diet in Treating Patients With Minimal Hepatic Encephalopathy

NCT02418039

Liver Cirrhosis

TERMINATED NA

Impact of Dietary Assessment and Intervention on Outcomes in Liver Cirrhosis Patients

NCT05259930

Sarcopenia Cirrhosis, Liver

RECRUITING NA

Short Term Outcomes in Hospitalized Patients With Liver Cirrhosis

NCT05848414

Liver Cirrhosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The progressive deterioration of liver tissue over time is a hallmark of chronic liver disorders (CLD). Liver diseases are linked to a number of risk factors, including environmental pollutants, genetics, and infectious diseases. The process of liver damage may be accelerated when multiple factors work together.

Due to their involvement in numerous metabolic pathways, trace elements are essential for preserving health. The liver plays a crucial role in controlling the metabolic pathway and transport, tissue distribution, toxicity, and trace element bioavailability. Certain metabolic illnesses are brought on by an excess or a shortage of certain trace elements, such as copper (Cu), magnesium (Mg), and zinc (Zn).

Zinc is necessary for DNA synthesis, RNA transcription, cell growth, protein synthesis, and regeneration. It also serves as a center of activity or cofactor for hundreds of enzymes (5). Numerous symptoms, such as anemia, dermatitis, stomatitis, alopecia, bedsores, decreased appetite, stunted growth, gonadal dysfunction, infection susceptibility, and taste problems, are brought on by zinc deficiency. Reduced albumin synthesis, low oral intake, increased urine excretion of zinc linked to portosystemic shunt, and impaired intestinal absorption are the causes of zinc insufficiency in CLD patients.

Magnesium is the fourth most abundant cation and the most prevalent intracellular ion. It has been connected to more than 300 enzymatic processes, including the cytolysis of antibodies, the synthesis of immunoglobin, and the adherence of resistant cells. Conversely, low magnesium levels in serum and liver tissue can slow the development of these conditions by interfering with mitochondrial activity, triggering inflammatory reactions, or causing metabolic anomalies.

This study aims to measure serum levels of zinc and magnesium in patients with chronic liver disease and to evaluate their correlation with clinic-laboratory variables.

This observational cross-sectional study will be performed on 80 subjects from the outpatient clinic and inpatient of the Tropical Medicine and Infectious Diseases Department and Pediatric Department at Tanta University Hospitals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Liver Disease and Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

60 healthy subjects as control.

serum zinc and magnesium

Intervention Type DIAGNOSTIC_TEST

participants will be subjected to laboratory investigations (complete blood picture, liver and kidney function tests, Prothrombin time, international normalized ratio (INR), serum zinc, and magnesium).

Chronic liver disease

80 patients with chronic liver disease diagnosed by physical examination, laboratory investigations, and imaging study.

This group will be subdivided into non-cirrhotic and cirrhotic liver groups.

serum zinc and magnesium

Intervention Type DIAGNOSTIC_TEST

participants will be subjected to laboratory investigations (complete blood picture, liver and kidney function tests, Prothrombin time, international normalized ratio (INR), serum zinc, and magnesium).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

serum zinc and magnesium

participants will be subjected to laboratory investigations (complete blood picture, liver and kidney function tests, Prothrombin time, international normalized ratio (INR), serum zinc, and magnesium).

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic liver disease diagnosed by physical examination, laboratory investigations, and imaging study.

Exclusion Criteria

1. Patients with Wilson disease.
2. Patients with chronic renal diseases.
3. Patients with IBD or any other cause of chronic diarrhea.
4. Drugs affecting levels of trace elements e.g. corticosteroids, digoxin thiazide, diuretics, and supplements 30 days before study.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes